Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 19, 2023 08:30 ET | Source: Cerevance

Cerevance Doses First Subject in Phase 1 Clinical Study of CVN293, a Selective Inhibitor of KCNK13 Designed to Selectively Modulate Neuroinflammation, for the Treatment of ALS and Alzheimer’s Disease

BOSTON, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on advancing novel, precision neuroscience therapeutics for central...
September 06, 2023 08:30 ET | Source: Cerevance

Cerevance to Present During the 6th Annual LSX World Congress USA

BOSTON, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on advancing novel, precision neuroscience therapeutics for central...
August 31, 2023 08:30 ET | Source: Cerevance

Cerevance Announces Presentation at the 22nd Society of Chemical Industry / Royal Society of Chemistry Medicinal Chemistry Symposium

BOSTON, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on advancing novel, precision neuroscience therapeutics for central...
August 28, 2023 08:30 ET | Source: Cerevance

Fierce Biotech Names Cerevance a “Fierce 15” Biotech Company of 2023

BOSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on advancing novel, precision neuroscience therapeutics for central...
July 10, 2023 08:30 ET | Source: Cerevance

Cerevance Announces Presentation at the Alzheimer’s Association International Conference

BOSTON, July 10, 2023 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on developing novel therapeutics for central nervous system (CNS)...
June 28, 2023 08:30 ET | Source: Cerevance

Cerevance Announces Presentation at the XVI European Meeting on Glial Cells in Health and Disease

BOSTON, June 28, 2023 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on developing novel therapeutics for central nervous system (CNS)...
June 26, 2023 08:30 ET | Source: Cerevance

Cerevance Announces Presentation at the Gordon Research Conference: Amyotrophic Lateral Sclerosis and Related Motor Neuron Diseases

BOSTON, June 26, 2023 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on developing novel therapeutics for central nervous system (CNS)...
May 16, 2023 08:30 ET | Source: Cerevance

Cerevance Announces Oral Presentation of Phase 1 Data on CVN766 at American Society of Clinical Psychopharmacology (ASCP)

BOSTON, May 16, 2023 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on developing novel therapeutics for central nervous system (CNS)...
May 09, 2023 08:30 ET | Source: Cerevance

Cerevance Announces Presentation at Neurodegeneration: New Biology Guiding the Next Generation of Therapeutic Development

BOSTON, May 09, 2023 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on developing novel therapeutics for central nervous system (CNS)...
May 08, 2023 08:30 ET | Source: Cerevance

Cerevance to Present at the 2023 RBC Capital Markets Global Healthcare Conference

BOSTON, May 08, 2023 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on central nervous system (CNS) diseases, today announced that Craig...